Global Conference on Liver & Hepatitis Venice, Italy | May 11-12, 2020

Alcantara J

doi:10 .4172/2327-4581.1000411

2020 Conference Announcement, Int J Ment Health Psychiatry Vol: 5 Issue: 3

Global Conference on Liver & Hepatitis Venice, Italy | May 11-12, 2020

Alcantara J

Research Director, International Chiropractic Pediatric Association, USA, E-mail: r_jalcantara@yahoo.com

Keywords: Hepatitis

Download PDF

Liver Disease Treatment Market Overview:

Liver diseases contains wide scope of complex conditions influencing the liver. Liver sickness treatment advertise is guaranteed to develop by virtue of neglected clinical needs and up and coming treatment modifications. Many novel agents has shown improvements in clinical trials for example obeticholic acid, thiazolidinediones and vitamin E for treatment of nonalcoholic fatty liver diseases. In Addition, according to American Cancer Society liver cancer rates increases 2.7% every year propelling the growth of market. Based on treatment type the market is bifurcated into Chemotherapy drugs, targeted therapy, anti-viral drugs, immunoglobulins, corticosteroids, vaccines, anti-rejection drugs/immunosuppressant.

By Geography in North America, Europe, APAC and LAMEA. North America is bifurcated into the U.S., Mexico and Canada whereas Europe have been further segmented into UK, Russia, Germany, Italy, France and rest of Europe. APAC comprises of China, India, Japan, South Korea, Taiwan and rest of Asia Pacific. LAMEA includes Latin America, Middle East and Africa.

Increasing incidences of liver diseases

Increasing incidences of obesity, metabolic syndrome, diabetes and cardiovascular disorders that lead to liver diseases are another major factor boosting the growth of liver disease treatment market. Additionally, increasing prevalence of liver disease due to side effects of other drugs such as acetaminophen and poor hygienic and sanitation conditions are expected to drive the market in the coming years.

Growing geriatric population

Structural dysfunction due to aging mainly leads to liver diseases. According to the National Institute of Aging, geriatric population is likely to increase by 86% till 2050. The increasing rates of geriatric population have resulted in rise of the incidences of liver diseases, which further escalating the demand of liver disease treatment market.